BreAX Biotech
Develops a breath-based diagnostic platform leveraging proprietary single-photon ionization-time-of-flight mass spectrometer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Series A | |
| Total Funding | 000k | ||
BreAX Biotech, legally known as Breax Biological Technology Co., Ltd., is a company operating in the diagnostic equipment industry, specializing in breath analysis for disease detection. The company was established in December 2018 by founder and CEO Alan Wang. His professional background includes serving as the vice president of 12 SIGMA Technologies and as the director of the surgical product department at Olympus China, providing him with extensive experience in the medical device sector's product, sales, marketing, and management aspects.
The firm's core business revolves around providing noninvasive, accurate, and low-cost screening and diagnostic solutions. Its target clients include clinics, hospitals, medical centers, and clinical research communities. BreAX Biotech's business model appears to be centered on the development and sale of its proprietary technology, which combines a hardware component—the "human exhaled breath detection mass spectrometer"—with artificial intelligence software. This integrated platform is designed to detect and analyze volatile organic compounds (VOCs) in human breath. These VOCs can serve as biomarkers for various conditions, particularly infectious diseases, cancers, and inflammatory diseases. The company has also developed a patented breath sample bag for the collection of alveolar gas.
A significant milestone was achieved in July 2021, when the company obtained a Class II CFDA certificate for its mass spectrometer. By that time, BreAX Biotech had also constructed a database of ten thousand breath samples. In February 2022, the company secured Series A funding from investors including Gaolue Capital, Primavera Venture Partners, Proxima Ventures (China), Goldport Capital, and Shenzhen Qianhai Greatwall Fund. The company has engaged in collaborations with several top hospitals in China, conducting research on serious diseases like tuberculosis, lung cancer, and esophageal cancer. The company's production facility in Hunan passed the GMP certification by the drug administration in January 2022.
Keywords: breath analysis, disease detection, diagnostic equipment, medical devices, volatile organic compounds, noninvasive diagnostics, mass spectrometry, artificial intelligence in healthcare, clinical research solutions, cancer screening, infectious disease detection, metabolomics, expiratory metabolomics, Alan Wang, precision medicine, medical biomarkers, CFDA certification, clinical diagnostics, Shenzhen biotech